Preexisting immunity to adenovirus in rhesus monkeys fails to prevent vector-induced toxicity. - Wikidata - wikimedia - TriplyDB

Preexisting immunity to adenovirus in rhesus monkeys fails to prevent vector-induced toxicity.

Preexisting immunity to adenovirus in rhesus monkeys fails to prevent vector-induced toxicity.

http://www.wikidata.org/entity/Q34365087

about

The interplay of post-translational modification and gene therapy Developments in the treatment of hemophilia B: focus on emerging gene therapy Evaluation of toxicity from high-dose systemic administration of recombinant adenovirus vector in vector-naive and pre-immunized mice.Modulation of TNFalpha, a determinant of acute toxicity associated with systemic delivery of first-generation and helper-dependent adenoviral vectors.Adenoviral vector immunity: its implications and circumvention strategies.The influence of innate and pre-existing immunity on adenovirus therapy Pre-existing immunity and passive immunity to adenovirus 5 prevents toxicity caused by an oncolytic adenovirus vector in the Syrian hamster model Efficient, long-term hepatic gene transfer using clinically relevant HDAd doses by balloon occlusion catheter delivery in nonhuman primates A porcine adenovirus with low human seroprevalence is a promising alternative vaccine vector to human adenovirus 5 in an H5N1 virus disease model Replicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies.Infection with host-range mutant adenovirus 5 suppresses innate immunity and induces systemic CD4+ T cell activation in rhesus macaques.Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications.Helper-dependent adenoviral vectors for liver-directed gene therapy.Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy.Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity Induction and comparison of SIV immunity in Ad5 naïve and Ad5 immune non-human primates using an Ad5 [E1-, E2b-] based vaccine.A novel and simple method for rapid generation of recombinant porcine adenoviral vectors for transgene expression An acute toxicology study with INGN 007, an oncolytic adenovirus vector, in mice and permissive Syrian hamsters; comparisons with wild-type Ad5 and a replication-defective adenovirus vector.Vaccination with adenovirus serotypes 35, 26, and 48 elicits higher levels of innate cytokine responses than adenovirus serotype 5 in rhesus monkeys Effect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed Syrian hamsters.Innate functions of immunoglobulin M lessen liver gene transfer with helper-dependent adenovirus.Helper-Dependent Adenoviral Vectors.Impact of intravenous infusion time on AAV8 vector pharmacokinetics, safety, and liver transduction in cynomolgus macaques.Development and assessment of human adenovirus type 11 as a gene transfer vector.Analysis of adenovirus sequestration in the liver, transduction of hepatic cells, and innate toxicity after injection of fiber-modified vectors A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity.Toward gene therapy for hemophilia A with novel adenoviral vectors: successes and limitations in canine models.Enhanced local delivery with reduced systemic toxicity: delivery, delivery, and delivery.Factors influencing retention of adenovirus within tumours following direct intratumoural injection.Challenges and Prospects for Helper-Dependent Adenoviral Vector-Mediated Gene Therapy.

P2860

Q26751281-E998C67E-3B20-4C61-9D09-BE690AA65AC5 Q26823376-F53D742E-06CB-4D15-BB82-BC32E33FFAF3 Q33364523-9B563A5C-CF38-416B-95DE-BA64C43C4AB3 Q33371239-F89CB8DD-86A6-45DE-86F2-024540058737 Q33565630-66F0D826-BD09-44DD-9E33-69225804E2E0 Q33655401-CA4212A2-7BB8-4137-A7AC-7690F68A1DF1 Q33713048-AA1B760B-D4D4-4B91-BC41-7D2341C54AB5 Q33713289-4C8D798C-415A-4B51-A7D9-C2728F76EDBD Q33778607-F3D73637-2C61-4B40-BC48-EAE369361FD1 Q33911986-34FCCD2B-C74B-41FF-B459-1DC65D370262 Q34155550-3E78FD73-E1DE-49E9-BF6B-33EA05849ACB Q34717992-281DCD27-5021-489A-89A5-3DFDBA3086D4 Q34982825-394864A6-7ED3-410F-B711-0E362EE72137 Q35131227-CA3DC943-3795-4A54-830B-60E80CB58581 Q35155049-44726B19-6B68-4903-9C0F-AD720CF42DF2 Q35317858-665F5D2F-2B11-40B4-A6AD-D19CFBBD9937 Q35641856-992D2F34-B294-432D-AC6B-A05350DBF744 Q36209165-83B01EDE-F21D-45C7-9070-01BF93A41263 Q36246264-889033BF-8AB8-4E0C-8AD5-B40F1C22590E Q37099738-56B56D67-A34F-47E9-BB3B-F00D846B24FE Q37499424-461A6550-7948-4F83-BBAA-410CF394974A Q37582126-6AC347D3-595F-4213-9BC6-14C9D19090DD Q39117333-47E083E9-E80E-4EB9-9423-EF8F449D5AC6 Q40441928-4B6826E1-FCE8-4F75-98E2-68081A29149D Q40815226-C57A5965-B6C8-43CA-A91D-35C7946CD3D8 Q42265160-1DDD435D-B2C8-4505-BCCD-9E179BB5E8B1 Q45858373-3A0837E1-9DCC-472D-8314-D2F8DE4304A3 Q45865369-927CC484-C3C8-4F69-A2B0-065EC6F1DFEA Q45875328-AD6ECA59-86A0-4477-B6F6-5681628BB2EB Q50977875-C6D9D5FA-E6BE-4919-990F-DA93D86E662F

P2860

Preexisting immunity to adenovirus in rhesus monkeys fails to prevent vector-induced toxicity.

http://www.wikidata.org/entity/Q34365087

description

2002 nî lūn-bûn

@nan

2002 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Preexisting immunity to adenov ...... event vector-induced toxicity.

@ast

Preexisting immunity to adenov ...... event vector-induced toxicity.

@en

Preexisting immunity to adenov ...... event vector-induced toxicity.

@nl

type

label

Preexisting immunity to adenov ...... event vector-induced toxicity.

@ast

Preexisting immunity to adenov ...... event vector-induced toxicity.

@en

Preexisting immunity to adenov ...... event vector-induced toxicity.

@nl

prefLabel

Preexisting immunity to adenov ...... event vector-induced toxicity.

@ast

Preexisting immunity to adenov ...... event vector-induced toxicity.

@en

Preexisting immunity to adenov ...... event vector-induced toxicity.

@nl

P1433

Q34365087-D9BA2737-2B39-4FE2-846E-3F1808E60539

P1476

Q34365087-33B24AD3-61F7-4E99-916B-347C14F27817

P2093

Q34365087-15A2F4FB-B7CE-4CDB-A4B5-E86399C247C1

Q34365087-26C3B037-8A70-414E-A330-55DBCE68DF27

Q34365087-5599061D-2719-47B2-8898-EF417DA6137D

Q34365087-66A56B7D-DF28-4F5A-89C5-0188AE19ABB4

Q34365087-67396D43-3A3B-438C-856C-201440B39B7E

Q34365087-8FA6F214-5B1B-492D-80A6-5DC11A4A3ACB

Q34365087-A28CA193-E81D-4AA1-9CDB-23C37737CE38

Q34365087-CA23BDEC-5D5B-4BC3-848B-C62587B7F0FE

Q34365087-FA357352-9183-48FF-824A-016AB2565947

P2860

Q34365087-00F76E2E-E76D-43D3-8E53-84676C75FF99

Q34365087-1104117A-4541-4C5C-A642-DC201DF69F99

Q34365087-31571441-E680-4CA9-B355-E78BD6242602

Q34365087-34AA0BD2-7F1D-4638-8F58-F56E25EA434A

Q34365087-36724FC9-47C9-42E2-853D-028F8C68E9A4

Q34365087-3B26F8B0-58B2-4FB9-873C-351DCBDB2B93

Q34365087-455BC26A-5622-4C44-AB6A-ED9DFB15C94F

Q34365087-49D7B8C4-7E51-446E-8781-5A91E93FCF31

Q34365087-4B476D90-A845-4EB3-BCC7-FDA37A1A5D26

Q34365087-4B94B133-4E27-431D-B704-B7388E9E65A8

P304

Q34365087-D32DF9BD-B23F-40E7-A8DA-75902D835AEC

P31

Q34365087-B48F4A6E-346A-4B88-9E36-6B477BC4D664

P356

Q34365087-D38359C8-FCC4-471A-9C1C-2FEF0AE7C9F7

P407

Q34365087-46A490B0-D9A5-41AC-9F98-907FB838C068

P433

Q34365087-CD41D7AD-EC3D-4335-9DA8-6A607FCF601C

P478

Q34365087-62B77337-605C-4D2F-BB66-91FFDB1172EE

P577

Q34365087-97F9D572-9795-466A-B056-9BBFB2090129

P698

Q34365087-6043D573-8013-44A6-89C5-353ABDE67437

P921

Q34365087-538C6399-EB08-446B-AAAD-A40E428414E0

P932

Q34365087-8D28DABF-8506-4F94-BDA0-F0656AC86130

P356

JVI.76.11.5711-5719.2002

P1433

Journal of Virology

P1476

Preexisting immunity to adenov ...... event vector-induced toxicity.

@en

P2093

Adam Bagg

http://www.w3.org/2001/XMLSchema#string

Andrei N Varnavski

http://www.w3.org/2001/XMLSchema#string

Guang-ping Gao

http://www.w3.org/2001/XMLSchema#string

James M Wilson

http://www.w3.org/2001/XMLSchema#string

Jean-Pierre Louboutin

http://www.w3.org/2001/XMLSchema#string

John Tazelaar

http://www.w3.org/2001/XMLSchema#string

Michael Schnell

http://www.w3.org/2001/XMLSchema#string

Qian-Chun Yu

http://www.w3.org/2001/XMLSchema#string

Yi Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Dendritic cells in the T-cell areas of lymphoid organs

The distinct surface of human blood dendritic cells, as observed after an improved isolation method.

Cytotoxic T-lymphocyte target proteins and their major histocompatibility complex class I restriction in response to adenovirus vectors delivered to mouse liver.

Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors.

"Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung

Immune responses to adenovirus and adeno-associated virus in humans.

Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily.

Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses

Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy.

CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells

P304

5711-5719

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.76.11.5711-5719.2002

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

76

http://www.w3.org/2001/XMLSchema#string

P577

2002-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11991999

http://www.w3.org/2001/XMLSchema#string

P921

P932

137042

http://www.w3.org/2001/XMLSchema#string